6/23/2014 11:07:03 AM
Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA), a leader of allogeneic CAR T-cell therapies, is pleased to announce it received a Scientific recommendation from the European Medicines Agency (EMA), in consultation with the European Commission, for UCART19, its lead product candidate in adoptive immunotherapy against CD19 expressing leukemias and lymphomas.
Help employers find you! Check out all the jobs and post your resume.
comments powered by